Labtec opens state-of-the-art manufacturing facility in Hamburg, Germany

By Alexandria Pesic

- Last updated on GMT

Related tags Pharmacology

German transdermal drug developer, Labtec, has opened what it claims is Europe’s most modern manufacturing facility for the production of transdermal drug delivery systems (TDS) and oral dispersible films (ODF) using its proprietary RapidFilm technology.

The new unit took one and a half years to complete, and is located within parent company tesa’s largest manufacturing site, tesa Werk Hamburg GmbH, just south of the German city of Hamburg.

Labtec says the facility provides industrial mass production services, and features state-of-the-art coating and drying lines with variable coating widths, as well as modern slitting machinery and high-precision, flexible converting and packaging equipment dedicated to TDS and ODF finished products.

Expert contributions

Ingo Lehrke, managing director of Langenfeld-headquartered Labtec, said the company was pleased to have the new facility up and running in such a timely fashion, and paid compliment to the contributions made to its construction not only by tesa experts, but also those of Hamburg-based skincare specialists, Bieresdorf Medical.

“It took only one and a half years from the initial planning phase until completion of construction and start of operation of the unit,” ​he said.

“This quick implementation is the result of an extremely close and dedicated cooperation between experts from tesa​, Bieresdorf and Labtec. We are now able to combine Labtec’s pharmaceutical know-how with tesa’s extensive manufacturing expertise to supply our customers with innovative drug delivery products.”

According to Labtec, the new Hamburg plant operates a clean-room environment, and is certified as fully good manufacturing practice (GMP) compliant following a three-day inspection by Hamburg’s health authorities in March this year.

Focused efforts

Tesa finalised a deal for Labtec in Novemeber2008, as it sought to focus its efforts on burgeoning markets in the healthcare sector.

Consequently the company – which is a leading manufacturer in the production of self-adhesive products and solutions for industry, trade and consumers – saw the acquisition of Labtec as “the next logical step” ​in pursuing its strategy of tapping into “high-yield markets of the future”.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers